| Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? |
The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-14 15:00:55 |
Czytaj oryginał (ang.) |
| uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript |
uniQure N.V. (NASDAQ:QURE ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director, Investor Relations Matt Kapusta - Chief Executive Officer Walid Abi-Saab - Chief Medical Officer Christian Klemt - Chief Financial Officer Conference Call Participants Luca Issi - RBC Debjit Chattopadhyay - Guggenheim Paul Matteis - Stifel Patrick Trucchio - H.C. |
seekingalpha.com |
2025-05-10 02:16:02 |
Czytaj oryginał (ang.) |
| UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates |
UniQure (QURE) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.36 per share a year ago. |
zacks.com |
2025-05-09 13:20:41 |
Czytaj oryginał (ang.) |
| uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress |
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31, 2025 expected to fund operations into second half of 2027 ~ ~ uniQure to host inaugural earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass. |
globenewswire.com |
2025-05-09 11:05:00 |
Czytaj oryginał (ang.) |
| uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data |
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here. |
seekingalpha.com |
2025-05-08 09:16:15 |
Czytaj oryginał (ang.) |
| uniQure to Announce First Quarter 2025 Financial Results |
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ |
globenewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? |
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-21 14:55:41 |
Czytaj oryginał (ang.) |
| uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 |
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth. |
seekingalpha.com |
2025-04-21 05:56:10 |
Czytaj oryginał (ang.) |
| uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting |
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact. |
seekingalpha.com |
2025-04-19 12:31:37 |
Czytaj oryginał (ang.) |
| Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? |
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday |
benzinga.com |
2025-04-17 14:27:12 |
Czytaj oryginał (ang.) |
| uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease |
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ |
globenewswire.com |
2025-04-17 11:17:00 |
Czytaj oryginał (ang.) |
| UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates |
UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago. |
zacks.com |
2025-02-27 11:35:26 |
Czytaj oryginał (ang.) |
| uniQure Announces 2024 Financial Results and Highlights Recent Company Progress |
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~ |
globenewswire.com |
2025-02-27 09:05:00 |
Czytaj oryginał (ang.) |
| uniQure N.V.: A Potential Huntington's Play |
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share. |
seekingalpha.com |
2025-02-26 03:47:34 |
Czytaj oryginał (ang.) |
| uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons |
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025. |
seekingalpha.com |
2025-02-20 17:07:14 |
Czytaj oryginał (ang.) |
| uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years |
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients. |
benzinga.com |
2025-02-07 15:04:43 |
Czytaj oryginał (ang.) |
| CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B |
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX in the treatment of hemophilia B Phase 3 HOPE-B data showed that a one-time treatment with HEMGENIX provided long-term bleed protection as mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from lead-in as compared to year four KING OF PRUSSIA, Pa. , Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B. |
prnewswire.com |
2025-02-07 11:12:00 |
Czytaj oryginał (ang.) |
| uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease |
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ |
globenewswire.com |
2025-02-03 09:05:00 |
Czytaj oryginał (ang.) |
| uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS |
~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ |
globenewswire.com |
2025-01-30 09:37:00 |
Czytaj oryginał (ang.) |
| uniQure Announces Pricing of its Public Offering |
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $75 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 661,764 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 10, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-01-08 09:05:00 |
Czytaj oryginał (ang.) |
| uniQure Announces Proposed Public Offering |
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-01-07 18:49:00 |
Czytaj oryginał (ang.) |
| Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? |
Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate. |
fool.com |
2024-12-15 06:31:00 |
Czytaj oryginał (ang.) |
| QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug |
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease. |
zacks.com |
2024-12-11 13:06:19 |
Czytaj oryginał (ang.) |
| uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease |
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ |
globenewswire.com |
2024-12-10 09:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet |
The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-29 12:57:19 |
Czytaj oryginał (ang.) |
| What Makes uniQure (QURE) a New Buy Stock |
uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-28 15:05:53 |
Czytaj oryginał (ang.) |
| uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy |
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE). |
globenewswire.com |
2024-11-21 09:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 169.2% in uniQure (QURE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-08 12:55:22 |
Czytaj oryginał (ang.) |
| UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates |
UniQure (QURE) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.88 per share a year ago. |
zacks.com |
2024-11-05 11:31:08 |
Czytaj oryginał (ang.) |
| uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress |
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~ |
globenewswire.com |
2024-11-05 09:05:00 |
Czytaj oryginał (ang.) |
| UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:18 |
Czytaj oryginał (ang.) |
| uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS |
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with three dose-escalating cohorts assessing the safety, tolerability and exploratory signs of efficacy of AMT-162 in individuals with SOD1-ALS. |
globenewswire.com |
2024-10-15 11:05:00 |
Czytaj oryginał (ang.) |
| uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease |
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure's investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.S., multi-center, open-label Phase I/IIa trial of AMT-191. |
globenewswire.com |
2024-09-23 11:05:00 |
Czytaj oryginał (ang.) |
| uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease |
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of AMT-191 in individuals with Fabry disease. |
globenewswire.com |
2024-08-15 11:05:00 |
Czytaj oryginał (ang.) |
| uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity |
uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end. |
seekingalpha.com |
2024-08-06 07:03:54 |
Czytaj oryginał (ang.) |
| UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates |
UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago. |
zacks.com |
2024-08-01 13:25:17 |
Czytaj oryginał (ang.) |
| uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update |
~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ |
globenewswire.com |
2024-08-01 11:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High? |
The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-07-26 14:55:29 |
Czytaj oryginał (ang.) |
| uniQure Announces Closing of Sale of Manufacturing Facility to Genezen |
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ |
globenewswire.com |
2024-07-23 11:05:00 |
Czytaj oryginał (ang.) |
| What Led To A 150% Rise In UniQure Stock In A Week? |
uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease. |
forbes.com |
2024-07-12 12:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet |
The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-07-10 14:55:27 |
Czytaj oryginał (ang.) |